{
    "eid": "2-s2.0-84966783616",
    "title": "Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B",
    "cover-date": "2016-06-01",
    "subject-areas": [
        {
            "$": "Hepatology",
            "@code": "2721"
        }
    ],
    "keywords": [
        "HBsAg quantification",
        "Hepatitis B core-related antigen",
        "Hepatitis B virus",
        "Pegylated interferon"
    ],
    "authors": [
        "Natthaya Chuaypen"
    ],
    "citedby-count": 69,
    "ref-count": 37,
    "ref-list": [
        "Hepatitis B virus infection",
        "Management of hepatitis B: Summary of a clinical research workshop",
        "Interferon Therapy for Chronic Hepatitis B",
        "Optimal therapy of chronic hepatitis B: How do I treat HBeAg-positive patients?",
        "Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan",
        "Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response",
        "HBsAg quantification: Useful for monitoring natural history and treatment outcome",
        "Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels",
        "Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection",
        "Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients",
        "Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation",
        "Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B",
        "Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D",
        "Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis",
        "HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy",
        "Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection",
        "Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B",
        "Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy",
        "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection",
        "An algorithm for the grading of activity in chronic hepatitis C",
        "A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma",
        "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load",
        "Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccdna load - down-regulated transcription of PgRNA has limited impact",
        "Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy",
        "The natural history and treatment of chronic hepatitis B: A critical evaluation of standard treatment criteria and end points",
        "Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma",
        "Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: A meta-analysis",
        "Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial",
        "Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B",
        "Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen\u2013Positive Chronic Hepatitis B Using On-Treatment Hepatitis B Surface Antigen Decline",
        "Hepatitis B surface antigen: Association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients",
        "Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients",
        "Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay",
        "Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: A clue from serum HBsAg levels",
        "Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B",
        "Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B",
        "Hepatitis B virus: Origin and evolution"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nagoya",
            "affilname": "Nagoya City University Graduate School of Medical Sciences",
            "affiliation-country": "Japan"
        }
    ],
    "funding": [
        "Japan Society for the Promotion of Science",
        "Japan Society for the Promotion of Science"
    ]
}